Medtronic plc — Form 10-K Summary
Period: Fiscal year ended April 29, 2022. The request metadata says “2021 Q4,” but this filing reports fiscal 2022 results, with fiscal 2021 as the prior-year comparison; it is not a standalone quarterly report. Medtronic is a global medical technology company operating through Cardiovascular, Medical Surgical, Neuroscience, and Diabetes segments.
Key financial results
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Net sales | $31.686 billion | $30.117 billion | +5% |
| Operating profit | $5.752 billion | $4.484 billion | +28% |
| Operating margin | 18.2% | 14.9% | +3.3 percentage points |
| Net income attributable to Medtronic | $5.039 billion | $3.606 billion | +40% |
| Diluted EPS | $3.73 | $2.66 | +40% |
| Cash from operating activities | $7.346 billion | $6.240 billion | +$1.106 billion |
| Free cash flow (non-GAAP) | $5.978 billion | $4.885 billion | +$1.093 billion |
| Interest expense | $553 million | $925 million | Down $372 million |
Revenue growth reflected recovery in global procedure volumes following pandemic-related declines in FY2021. It was partly offset by supply constraints, especially in the fourth quarter, and COVID-19 effects in the U.S. and China. Reported results included substantial unusual items: notably $881 million of HVAD-related impairment and costs, as well as $1.733 billion of intangible-asset amortization. Management’s non-GAAP diluted EPS was $5.55 versus $4.42; these adjusted figures exclude specified items and are not U.S. GAAP measures.
Segment performance
- Cardiovascular: $11.423 billion, up 6%.
- Medical Surgical: $9.141 billion, up 5%; Respiratory, Gastrointestinal, & Renal declined 7%, largely as ventilator demand normalized.
- Neuroscience: $8.784 billion, up 7%.
- Diabetes: $2.338 billion, down 3%, with U.S. declines partly offset by international growth.
Liquidity, debt, and capital allocation
- At April 29, 2022, cash and cash equivalents were $3.714 billion and current investments were $6.859 billion. Current assets totaled $23.059 billion versus current liabilities of $12.394 billion.
- Total debt was approximately $24.1 billion, down from $26.4 billion a year earlier. Current debt obligations rose to $3.742 billion, principally reflecting notes due in FY2023.
- Medtronic reported $7.346 billion of operating cash flow and $1.368 billion of capital expenditures. Financing cash outflow was $5.336 billion, including $3.383 billion of dividends and $2.544 billion of share repurchases.
- The company had no commercial paper outstanding and no borrowings under its $3.5 billion revolving credit facility at year-end. Long-term debt ratings were unchanged at S&P A and Moody’s A3.
- The quarterly dividend was $0.63 per share in FY2022; the company announced an increase to $0.68 per share for FY2023’s first quarter.
Material changes, outlook, and risks
- Medtronic stopped distribution and sale of the HVAD System in June 2021 after clinical comparisons indicated less favorable outcomes versus another device. It recorded $881 million in impairment and related costs and continued support obligations for approximately 3,500 implanted patients.
- Management provided no specific consolidated revenue or earnings guidance in the supplied filing text. Its outlook emphasized uncertainty around procedure volumes, COVID-19 and staffing effects, supply-chain constraints, inflation and labor costs, pricing and reimbursement pressure, China tender pricing, foreign exchange, and geopolitical developments.
- A December 2021 FDA warning letter concerning MiniMed 600-series pumps and a remote controller remained unresolved; the company said this could limit U.S. product launches before resolution.
- Other notable exposures include a pending IRS dispute over income allocation involving Puerto Rico manufacturing, with $1.661 billion of total reserves for uncertain tax positions; product-liability and other litigation; regulatory approval and product-quality risks; and cybersecurity and supply-chain risks.
- Subsequent events: Medtronic agreed to contribute its Renal Care Solutions business, which generated $325 million of FY2022 revenue, to a planned 50/50 joint venture with DaVita, expected to close in 2023. The filing also disclosed the May 2022 Intersect ENT acquisition for approximately $1.2 billion and post-year-end yen borrowings used to redeem debt.
- The independent auditor issued an unqualified opinion and concluded internal control over financial reporting was effective. The auditor identified the Puerto Rico-related uncertain tax position as a critical audit matter.
Most important facts for investors to verify
- Whether procedure-volume recovery and segment growth persist despite COVID-19 effects, staffing shortages, and supply constraints.
- Whether inflation, product mix, pricing, and reimbursement pressures erode margins.
- Progress on HVAD patient support and the financial sufficiency of related accruals.
- Resolution and potential financial impact of the Puerto Rico tax case and other tax uncertainties.
- Resolution of the FDA warning letter and implications for Diabetes product approvals and launches.
- Potential litigation outcomes, including hernia mesh claims, and execution and economics of the DaVita transaction.
- Debt repayment needs and liquidity after the disclosed post-year-end borrowing and note redemptions.